Amid rising competition, Teva Pharmaceutical Industries intends to divest its active pharmaceutical ingredients (API) unit to focus on other businesses, including in-house drug development. In 2023, the 4,300-employee unit, a provider of small-molecule APIs, recorded sales of $568 million to third parties—a 16% decrease from 2022. The business also supplies APIs to Teva. The firm expects to complete the divestiture in the first half of 2025.
I'm rather surprised that Teva is selling its API business, but maybe I don't understand how their company works...
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20